[{"address1": "1201 Orange Street", "address2": "Suite 600", "city": "Wilmington", "state": "DE", "zip": "19801", "country": "United States", "phone": "484 254 6134", "website": "https://www.nrxpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Jonathan C. Javitt M.D., M.P.H.", "age": 67, "title": "Co-Founder, Chief Scientist Officer, Chairman & Interim CEO", "yearBorn": 1957, "fiscalYear": 2024, "totalPay": 825000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew Patrick Duffy", "age": 61, "title": "Chief Business Officer & Co-CEO of Hope Therapeutics", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 338000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael S. Abrams", "age": 54, "title": "Chief Financial Officer", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Riccardo  Panicucci Ph.D.", "age": 63, "title": "Chief Manufacturing & Technology Officer", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 240000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Suzanne  Messere", "title": "Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Philip T. Lavin Ph.D.", "age": 77, "title": "Chief Methodologist", "yearBorn": 1947, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.44, "open": 2.46, "dayLow": 2.4, "dayHigh": 2.58, "regularMarketPreviousClose": 2.44, "regularMarketOpen": 2.46, "regularMarketDayLow": 2.4, "regularMarketDayHigh": 2.58, "payoutRatio": 0.0, "beta": 1.917, "forwardPE": 10.24, "volume": 478465, "regularMarketVolume": 478465, "averageVolume": 478439, "averageVolume10days": 591120, "averageDailyVolume10Day": 591120, "bid": 1.73, "ask": 2.7, "bidSize": 2, "askSize": 2, "marketCap": 75789184, "fiftyTwoWeekLow": 1.43, "fiftyTwoWeekHigh": 6.01, "allTimeHigh": 769.9, "allTimeLow": 1.1, "priceToSalesTrailing12Months": 313.17844, "fiftyDayAverage": 2.5446, "twoHundredDayAverage": 2.648645, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 75001928, "profitMargins": 0.0, "floatShares": 20326385, "sharesOutstanding": 29605150, "sharesShort": 1744957, "sharesShortPriorMonth": 1358460, "sharesShortPreviousMonthDate": 1763078400, "dateShortInterest": 1765756800, "sharesPercentSharesOut": 0.0589, "heldPercentInsiders": 0.097729996, "heldPercentInstitutions": 0.25062, "shortRatio": 3.7, "shortPercentOfFloat": 0.0627, "impliedSharesOutstanding": 29605150, "bookValue": -0.93, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -38060000, "trailingEps": -2.31, "forwardEps": 0.25, "lastSplitFactor": "1:10", "lastSplitDate": 1712016000, "enterpriseToRevenue": 309.925, "enterpriseToEbitda": -4.935, "52WeekChange": 0.67320263, "SandP52WeekChange": 0.17318606, "quoteType": "EQUITY", "currentPrice": 2.56, "targetHighPrice": 47.0, "targetLowPrice": 25.0, "targetMeanPrice": 36.5, "targetMedianPrice": 37.0, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 7184000, "totalCashPerShare": 0.256, "ebitda": -15199000, "totalDebt": 10256000, "quickRatio": 0.259, "currentRatio": 0.294, "totalRevenue": 242000, "revenuePerShare": 0.014, "returnOnAssets": -0.97826, "grossProfits": 145000, "freeCashflow": 2985500, "operatingCashflow": -12497000, "grossMargins": 0.59916997, "ebitdaMargins": 0.0, "operatingMargins": -17.01653, "financialCurrency": "USD", "symbol": "NRXP", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1512397800000, "postMarketChangePercent": 0.39062464, "postMarketPrice": 2.57, "postMarketChange": 0.00999999, "regularMarketChange": 0.12, "regularMarketDayRange": "2.4 - 2.58", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 478439, "fiftyTwoWeekLowChange": 1.13, "fiftyTwoWeekLowChangePercent": 0.79020983, "fiftyTwoWeekRange": "1.43 - 6.01", "fiftyTwoWeekHighChange": -3.4500003, "fiftyTwoWeekHighChangePercent": -0.5740433, "fiftyTwoWeekChangePercent": 67.32027, "earningsTimestampStart": 1763413200, "earningsTimestampEnd": 1763413200, "earningsCallTimestampStart": 1763386200, "earningsCallTimestampEnd": 1763386200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.31, "epsForward": 0.25, "epsCurrentYear": -1.33, "priceEpsCurrentYear": -1.924812, "fiftyDayAverageChange": 0.015399933, "fiftyDayAverageChangePercent": 0.0060520056, "twoHundredDayAverageChange": -0.08864498, "twoHundredDayAverageChangePercent": -0.03346805, "priceToBook": -2.7526882, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "NeuroRx, Inc.", "nameChangeDate": "2025-12-26", "averageAnalystRating": "1.0 - Strong Buy", "cryptoTradeable": false, "marketState": "CLOSED", "shortName": "NRX Pharmaceuticals, Inc.", "longName": "NRx Pharmaceuticals, Inc.", "regularMarketChangePercent": 4.91803, "regularMarketPrice": 2.56, "corporateActions": [], "postMarketTime": 1766796554, "regularMarketTime": 1766782800, "exchange": "NCM", "messageBoardId": "finmb_319388181", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "displayName": "NRx Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-12-27"}]